Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Blue Sky Radiomics: an Observational Study on Computed Tomography as an Image-based Predictive Marker of Response to Chemoradiation Followed by Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer (NSCLC).

NCT04364776 is registered in ClinicalTrials.gov with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor.

NCT NCT04364776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Blue Sky Radiomics: an Observational Study on Computed Tomography as an Image-based Predictive Marker of Response to Chemoradiation Followed by Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer (NSCLC).
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Observational
Overall status
Unknown status
Start date
January 15, 2020
Completion date
December 15, 2024
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, lung cancer stage iii